{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T15:15:52Z","timestamp":1758122152163},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,28]]},"DOI":"10.7759\/cureus.39613","type":"journal-article","created":{"date-parts":[[2023,5,28]],"date-time":"2023-05-28T22:01:56Z","timestamp":1685311316000},"source":"Crossref","is-referenced-by-count":2,"title":["Daptomycin-Induced Pulmonary Toxicity: A Case Series"],"prefix":"10.7759","author":[{"given":"Yamini I","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarasija","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srinivasarao","family":"Ramakrishna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pius","family":"Ochieng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Daptomycin","author":"Patel S","year":"2022","unstructured":"Patel S, Saw S. Daptomycin. StatPearls. StatPearls Publishing, Treasure Island; 2022."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2007.05.180","article-title":"Daptomycin","volume":"55","author":"Enoch DA","year":"2007","unstructured":"Enoch DA, Bygott JM, Daly ML, Karas JA. Daptomycin. J Infect. 2007, 55:205-13. 10.1016\/j.jinf.2007.05.180","journal-title":"J Infect"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac577","article-title":"Seventeen cases of daptomycin-induced eosinophilic pneumonia in a cohort of patients treated for bone and joint infections: proposal for a new algorithm","volume":"9","author":"Pham TT","year":"2022","unstructured":"Pham TT, Garreau R, Craighero F, Cottin V, Said BB, Goutelle S, Ferry T. Seventeen cases of daptomycin-induced eosinophilic pneumonia in a cohort of patients treated for bone and joint infections: proposal for a new algorithm. Open Forum Infect Dis. 2022, 9:ofac577. 10.1093\/ofid\/ofac577","journal-title":"Open Forum Infect Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh546","article-title":"Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections","volume":"55","author":"Steenbergen JN","year":"2005","unstructured":"Steenbergen JN, Alder J, Thorne GM, Tally FP. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother. 2005, 55:283-8. 10.1093\/jac\/dkh546","journal-title":"J Antimicrob Chemother"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1086\/430352","article-title":"Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact","volume":"191","author":"Silverman JA","year":"2005","unstructured":"Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005, 191:2149-52. 10.1086\/430352","journal-title":"J Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.9010-17","article-title":"Daptomycin-induced eosinophilic pneumonia and a review of the published literature","volume":"57","author":"Higashi Y","year":"2018","unstructured":"Higashi Y, Nakamura S, Tsuji Y, et al.. Daptomycin-induced eosinophilic pneumonia and a review of the published literature. Intern Med. 2018, 57:253-8. 10.2169\/internalmedicine.9010-17","journal-title":"Intern Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009688","article-title":"Drug-induced eosinophilic pneumonia: a review of 196 case reports","volume":"97","author":"Bartal C","year":"2018","unstructured":"Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: a review of 196 case reports. Medicine (Baltimore). 2018, 97:e9688. 10.1097\/MD.0000000000009688","journal-title":"Medicine (Baltimore)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1086\/652656","article-title":"Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases","volume":"50","author":"Miller BA","year":"2010","unstructured":"Miller BA, Gray A, Leblanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis. 2010, 50:e63-8. 10.1086\/652656","journal-title":"Clin Infect Dis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac065","article-title":"Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia","volume":"9","author":"West KA","year":"2022","unstructured":"West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic syndromes associated with daptomycin use: re-exposure hypersensitivity pneumonitis and prior peripheral eosinophilia. Open Forum Infect Dis. 2022, 9:ofac065. 10.1093\/ofid\/ofac065","journal-title":"Open Forum Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10040446","article-title":"Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection","volume":"10","author":"Soldevila-Boixader L","year":"2021","unstructured":"Soldevila-Boixader L, Villanueva B, Ulldemolins M, et al.. Risk factors of daptomycin-induced eosinophilic pneumonia in a population with osteoarticular infection. Antibiotics (Basel). 2021, 10:10.3390\/antibiotics10040446","journal-title":"Antibiotics (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia - a systematic review","volume":"5","author":"Uppal P","year":"2016","unstructured":"Uppal P, LaPlante KL, Gaitanis MM, Jankowich MD, Ward KE. Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control. 2016, 5:55. 10.1186\/s13756-016-0158-8","journal-title":"Antimicrob Resist Infect Control"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2016.09.001","article-title":"Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature","volume":"23","author":"Hirai J","year":"2017","unstructured":"Hirai J, Hagihara M, Haranaga S, et al.. Eosinophilic pneumonia caused by daptomycin: six cases from two institutions and a review of the literature. J Infect Chemother. 2017, 23:245-9. 10.1016\/j.jiac.2016.09.001","journal-title":"J Infect Chemother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11020254","article-title":"Factors associated with daptomycin-induced eosinophilic pneumonia","volume":"11","author":"Ishikawa K","year":"2022","unstructured":"Ishikawa K, Matsuo T, Tsuda Y, Rahman M, Uehara Y, Mori N. Factors associated with daptomycin-induced eosinophilic pneumonia. Antibiotics (Basel). 2022, 11:10.3390\/antibiotics11020254","journal-title":"Antibiotics (Basel)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060710","article-title":"A retrospective study on the effectiveness and safety of vancomycin versus daptomycin in hemodialysis patients","volume":"11","author":"Kato H","year":"2022","unstructured":"Kato H, Hagihara M, Kato M, et al.. A retrospective study on the effectiveness and safety of vancomycin versus daptomycin in hemodialysis patients. Antibiotics (Basel). 2022, 11:10.3390\/antibiotics11060710","journal-title":"Antibiotics (Basel)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/8525789","article-title":"Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery","volume":"2017","author":"Rachid M","year":"2017","unstructured":"Rachid M, Ahmad K, Saunders-Kurban M, Fatima A, Shah A, Nahhas A. Daptomycin-induced acute eosinophilic pneumonia: late onset and quick recovery. Case Rep Pulmonol. 2017, 2017:8525789. 10.1155\/2017\/8525789","journal-title":"Case Rep Pulmonol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2165\/11597460-000000000-00000","article-title":"Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports","volume":"35","author":"Kim PW","year":"2012","unstructured":"Kim PW, Sorbello AF, Wassel RT, Pham TM, Tonning JM, Nambiar S. Eosinophilic pneumonia in patients treated with daptomycin: review of the literature and US FDA adverse event reporting system reports. Drug Saf. 2012, 35:447-57. 10.2165\/11597460-000000000-00000","journal-title":"Drug Saf"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00221811","article-title":"Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia","volume":"41","author":"Rhee CK","year":"2013","unstructured":"Rhee CK, Min KH, Yim NY, Lee JE, Lee NR, Chung MP, Jeon K. Clinical characteristics and corticosteroid treatment of acute eosinophilic pneumonia. Eur Respir J. 2013, 41:402-9. 10.1183\/09031936.00221811","journal-title":"Eur Respir J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/157329-daptomycin-induced-pulmonary-toxicity-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:03:39Z","timestamp":1707509019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/157329-daptomycin-induced-pulmonary-toxicity-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,28]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.39613","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5,28]]}}}